These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 35390480)

  • 1. Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients.
    Hoffman TW; Meek B; Rijkers GT; van Kessel DA
    Transpl Immunol; 2022 Jun; 72():101599. PubMed ID: 35390480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
    Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
    Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of the SARS-CoV-2 mRNA vaccine in lung transplant recipients: a possible trigger of rejection.
    Goda Y; Nakajima D; Tanaka S; Yamada Y; Yutaka Y; Unagami K; Yoshikawa M; Egawa H; Date H
    Gen Thorac Cardiovasc Surg; 2023 Apr; 71(4):251-257. PubMed ID: 36289168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.
    Charmetant X; Espi M; Benotmane I; Barateau V; Heibel F; Buron F; Gautier-Vargas G; Delafosse M; Perrin P; Koenig A; Cognard N; Levi C; Gallais F; Manière L; Rossolillo P; Soulier E; Pierre F; Ovize A; Morelon E; Defrance T; Fafi-Kremer S; Caillard S; Thaunat O
    Sci Transl Med; 2022 Mar; 14(636):eabl6141. PubMed ID: 35103481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipients.
    Hirama T; Akiba M; Shundo Y; Watanabe T; Watanabe Y; Oishi H; Niikawa H; Okada Y
    J Infect Chemother; 2022 Aug; 28(8):1153-1158. PubMed ID: 35599079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
    Toniutto P; Falleti E; Cmet S; Cussigh A; Veneto L; Bitetto D; Fornasiere E; Fumolo E; Fabris C; Sartor A; Peressutti R; Curcio F; Regattin L; Grillone L
    J Hepatol; 2022 Jul; 77(1):152-162. PubMed ID: 35283215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients.
    Sakuraba A; Luna A; Micic D
    Viruses; 2022 Aug; 14(8):. PubMed ID: 36016444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients.
    Vanlerberghe B; Vrij C; Bogaerts K; Vermeersch P; Lagrou K; Molenberghs G; Rega F; Ceulemans LJ; van Raemdonck D; Jochmans I; Monbaliu D; Pirenne J; Vanuytsel T; Gillard P; Schoemans H; Cleemput JV; Kuypers D; Vos R; Nevens F; Verbeek J
    J Med Virol; 2023 Apr; 95(4):e28736. PubMed ID: 37185854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic.
    Reischig T; Kacer M; Vlas T; Drenko P; Kielberger L; Machova J; Topolcan O; Kucera R; Kormunda S
    Am J Transplant; 2022 Mar; 22(3):801-812. PubMed ID: 34860470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients.
    Huang HJ; Yi SG; Mobley CM; Saharia A; Bhimaraj A; Moore LW; Kloc M; Adrogue HE; Graviss EA; Nguyen DT; Eagar TN; Jones SL; Ankoma-Sey V; MacGillivray TE; Knight RJ; Gaber AO; Ghobrial RM
    Clin Transplant; 2022 May; 36(5):e14600. PubMed ID: 35083796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Ui M; Hirama T; Akiba M; Honda M; Kikuchi T; Okada Y
    Vaccine; 2023 Jul; 41(31):4534-4540. PubMed ID: 37328349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The humoral immune response to the BNT 162B2 vaccine in pediatrics on renal replacement therapy.
    Alshami A; Bahbah H; Al Attas R; Aldokhi F; Azzam A
    Pediatr Transplant; 2024 May; 28(3):e14712. PubMed ID: 38553800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients.
    Cuadrado A; Del Barrio M; Fortea JI; Amigo L; San Segundo D; Rodriguez-Cundin MP; Rebollo MH; Fernandez-Santiago R; Castillo F; Achalandabaso M; Echeverri J; Anderson EJ; Rodríguez-Sanjuan JC; López-Hoyos M; Crespo J; Fábrega E
    Hepatol Commun; 2022 Jul; 6(7):1673-1679. PubMed ID: 35344281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients.
    Gallais F; Renaud-Picard B; Solis M; Laugel E; Soulier E; Caillard S; Kessler R; Fafi-Kremer S
    J Heart Lung Transplant; 2022 Oct; 41(10):1429-1439. PubMed ID: 35953352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant Recipients.
    Grupper A; Rabinowich L; Ben-Yehoyada M; Katchman E; Baruch R; Freund T; Hagin D; Shlomo SB; Schwartz D; Schwartz IF; Shashar M; Bassat OK; Halperin T; Turner D; Saiag E; Goykhman Y; Shibolet O; Levy S; Houri I; Katchman H
    Transplant Proc; 2022; 54(6):1439-1445. PubMed ID: 35346486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients.
    Biagio P; Rosa C; Nicola SM; Fabrizio S; Amerigo P; Giulia Z; Riccardo S; Riccardo V; Paolo R; Lorenzo S; Ivan G; Federico Ii Covid Team
    Viruses; 2022 Sep; 14(9):. PubMed ID: 36146758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroconversion after SARS-CoV-2 vaccination is protective against severe COVID-19 disease in heart transplant recipients.
    Kugler S; Vári DK; Veres DS; Király Á; Teszák T; Parázs N; Tarjányi Z; Drobni Z; Szakál-Tóth Z; Prinz G; Miheller P; Merkely B; Sax B
    Immun Inflamm Dis; 2023 Nov; 11(11):e1086. PubMed ID: 38018598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Correlation Between Responders and Non-Responders to the Second Coronavirus Disease Vaccination In Kidney Transplant Recipients: A Retrospective Single-Center Cohort Study.
    Matsunami M; Suzuki T; Sugihara S; Toishi T; Nagaoka K; Fukuda J; Ohara M; Takanashi Y; Ochi A; Yashima J; Kuji H; Matsue K
    Transplant Proc; 2022; 54(6):1483-1488. PubMed ID: 35868872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients.
    Meunier L; Sanavio M; Dumortier J; Meszaros M; Faure S; Ursic Bedoya J; Echenne M; Boillot O; Debourdeau A; Pageaux GP
    Liver Int; 2022 Aug; 42(8):1872-1878. PubMed ID: 35338550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric solid organ transplant recipients demonstrate robust cell-mediated and humoral responses to three doses of mRNA SARS-CoV-2 vaccine.
    Bratic JS; Gans HA; Chen SF; Banaei N; Johnston EM; Sear K; Samreth S; Nadimpalli SS
    Am J Transplant; 2022 Dec; 22(12):3047-3052. PubMed ID: 36083190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.